GlassScriptPhysician profile
Mark William Mccord
NPI 1639117401
$473.55
in general payments reported to CMS, 2019-2025
14 companies · $63.27 in 2025
The $63.27 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $31.32 · 2022: $36.36 · 2023: $129 · 2024: $23.96 · 2025: $63.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $216.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $94.49 | 2019-2020 | |
| Elekta, INC. | $77.96 | 2019 | |
| Eisai INC. | $45.70 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $41.58 | 2023 | Orgovyx |
| Teleflex LLC | $32.13 | 2025 | Barrigel |
| Myriad Genetic Laboratories, INC. | $31.14 | 2025 | Prolaris |
| Astrazeneca Pharmaceuticals LP | $23.67 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $23.11 | 2023 | Tazverik |
| Janssen Biotech, INC. | $20.74 | 2022 | |
| Kyowa Kirin, INC. | $18.73 | 2023 | Poteligeo |
| Fortovia Therapeutics, INC. | $16.74 | 2019 | |
| Tactile Systems Technology INC | $16.41 | 2019 | |
| Puma Biotechnology, INC. | $15.62 | 2022 | |
| Boston Scientific Corporation | $15.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mccord listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.